London, United Kingdom
SPARTA Biodiscovery, founded in 2022, is a promising spin-out from Imperial College London, poised to make significant strides in the Biotechnology and Health and Wellness industries. The company's slogan, "Enabling nanoformulations for next-generation therapeutics," underscores its mission to revolutionize therapeutic development through innovative technologies.
The core innovation, SPARTA® (Single Particle Automated Raman Trapping Analysis), represents a breakthrough in analytical technology. It offers automated, label-free comprehensive characterization of nanoformulations, positioning it as a pivotal tool for researchers and developers. Currently offered as a service, plans to introduce it as a benchtop instrument are underway, promising broader accessibility and application.
Recently, SPARTA Biodiscovery secured a £3.50M Seed Round investment on 28 September 2023, led by Sartorius. This funding positions the company well for growth, enabling further development and commercialization efforts. Headquartered in the United Kingdom, SPARTA Biodiscovery stands at the forefront of biotechnology innovation.
